Enfoque otorrinolaringológico de la granulomatosis con poliangeítis (de Wegener) Otolaryngologic approach to granulomatosis with polyangitis (Wegener’s)

Contenido principal del artículo

Jorge Luis Alfredo Herrera Ariza
Perla Villamor Rojas

Resumen

Introducción: La granulomatosis con poliangeítis (de Wegener) es una enfermedad poco frecuente, sin embargo, el 80 a 90% de los casos tienen manifestaciones otorrinolaringológicas, muchas como único síntoma inicial de la enfermedad. Objetivos: El propósito de este artículo es revisar la literatura disponible actualizada sobre granulomatosis con poliangeítis: manifestaciones clínicas, estándares de enfoque, diagnóstico y tratamiento en otorrinolaringología. Diseño: Revisión narrativa de la literatura. Materiales y métodos: Revisión de la literatura mediante búsqueda selectiva por términos MeSH: Otorhinolaryngologic Diseases, Granulomatosis with polyangiitis, Wegener Granulomatosis, de las bases de datos:
MEDLINE, Current Contents, Cochrane, Pubmed y Scielo, entre los años 2000 y 2014. Resultados: Se revisaron 39 artículos según los requerimientos de los objetivos. La evidencia científica actual reconoce la importancia del conocimiento sobre granulomatosis con poliangeítis (de Wegener) en otorrinolaringología, para obtener diagnósticos tempranos y ofrecer manejos oportunos. Conclusiones: El diagnóstico y tratamiento tempranos de la granulomatosis con poliangeítis (de Wegener) son las únicas herramientas para mejorar el pronóstico y calidad de vida de los pacientes con esta enfermedad.

Introduction: Granulomatosis with polyangiitis (Wegener’s) is a rare disease,
however 80% to 90% of the cases have otolaryngologic manifestations, many as initial symptoms of the disease. Objectives: The purpose of this article is to review the current literature about granulomatosis with polyangiitis: Clinic manifestations, approach standards, diagnosis and treatment in otolaryngology. Design: Narrative review. Materials and methods: Literature review by selective search for MeSH terms: Otorhinolaryngologic Diseases, granulomatosis with polyangiitis, Wegener
granulomatosis, in the databases: MEDLINE, Current Contents, Cochrane, PubMed and SciELO, between 2000 and 2014. Results: 39 articles were reviewed according to the requirements of the objectives. Current scientific evidence recognizes the importance of the knowledge about granulomatosis with polyangiitis (Wegener’s) in otolaryngology, in order to give an early diagnosis and to provide an opportune treatment. Conclusions: Early diagnosis and treatment of granulomatosis with polyangiitis (Wegener’s) are the only tools to change the prognosis as well as quality of life of patients with this disease.

Descargas

Los datos de descargas todavía no están disponibles.

Detalles del artículo

Cómo citar
1.
Herrera Ariza JLA, Villamor Rojas P. Enfoque otorrinolaringológico de la granulomatosis con poliangeítis (de Wegener) Otolaryngologic approach to granulomatosis with polyangitis (Wegener’s). Acta otorrinolaringol cir cabeza cuello [Internet]. 14 de agosto de 2018 [citado 23 de junio de 2021];42(4):254-62. Disponible en: https://revista.acorl.org.co/index.php/acorl/article/view/150
Sección
Revisiones
Biografía del autor/a

Jorge Luis Alfredo Herrera Ariza, Fundación Universitaria de Ciencias de la Salud.

Otorrinolaringólogo, Jefe de Servicio de Otorrinolaringología, Hospital de San José. Bogotá, Colombia - Fundación Universitaria
de Ciencias de la Salud.

Perla Villamor Rojas, Hospital de San José. Bogotá, Colombia.

Residente de Otorrinolaringología, II año, Fundación Universitaria de Ciencias de la Salud - Hospital de San José. Bogotá, Colombia.

Citas

Almouhawis HA, Leao JC, Fedele S, Porter SR. Wegener’s granulomatosis: a review of clinical features and an update in diagnosis and treatment. J Oral Pathol Med. 2013; 42(7): 507-16.

Finkielman JD, Lee AS, Hummel AM, Viss MA, Jacob GL, Homburger HA, Peikert T, Hoffman GS, Merkel PA, Spiera R, St Clair EW, Davis JC Jr, McCune WJ, Tibbs AK, Ytterberg SR, Stone JH, Specks U; WGET Research Group. ANCA are detectable in nearly all patients with active severe Wegener’s granulomatosis. Am J Med. 2007; 120(7): 643.e9-14.

Iglesias GA, Restrepo JF, Valle R, Osorio E. Historia de las vasculitis. Rev. Colomb. Reumatol. 2002; 9(2): 87-121.

Rosen MJ. Dr. Friedrich Wegener, the ACCP, and History. Chest. 2007; 132(3): 739-41.

Rosen MJ. Dr. Friedrich Wegener and the ACCP, Revisited. Chest 2007; 132(6): 1723-4.

Falk RJ, Gross WL, Guillevin L, Hoffman GS, Jayne DR, Jennette JC, et al. American College of Rheumatology; American Society of Nephrology; European League Against Rheumatism. Granulomatosis with polyangiitis (Wegener’s): an alternative name for Wegener’s granulomatosis. Arthritis Rheum. 2011; 63(4): 863–4.

Ntatsaki E, Watts RA, Scott DG. Epidemiology of ANCAassociated vasculitis. Rheum Dis Clin North Am. 2010; 36(3): 447–61.

Ochoa R, Ramirez F, Quintana G, Toro C, Cañas C, Osio L, et al. Epidemiología de las vasculitis primarias en Colombia y su relación con lo informado para Latinoamérica. Rev. Colomb. Reumatol. 2009; 16(3): 248-263.

Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013; 65(1): 1-11.

Knight A, Sandin S, Askling J. Increased risk of autoimmune disease in families with Wegener’s granulomatosis. J Rheumatol. 2010; 37(12): 2553-8.

Arning L, Holle JU, Harper L, Millar DS, Gross WL, Epplen JT, et al. Are there specific genetic risk factors for the different forms of ANCA-associated vasculitis? Ann Rheum Dis. 2011; 70(4): 707–708.

Csernok E, Gross WL. Current understanding of the pathogenesis of granulomatosis with polyangiitis (Wegener’s). Expert Rev Clin Immunol. 2013; 9(7): 641-8.

Kesel N, Köhler D, Herich L, Laudien M, Holl-Ulrich K, Jüngel A, et al. Cartilage destruction in granulomatosis with polyangiitis (Wegener’s granulomatosis) is mediated by human fibroblasts after transplantation into immunodeficient mice. Am J Pathol. 2012; 180(5): 2144–2155.

Jennette JC, Falk RJ. New insight into the pathogenesis of vasculitis associated with antineutrophil cytoplasmic autoantibodies. Curr Opin Rheumatol. 2008; 20(1); 55–60.

Schlieben DJ, Korbet SM, Kimura RE, Schwartz MM, Lewis EJ. Pulmonary-renal syndrome in a newborn with placental transmission of ANCAs. Am J Kidney Dis. 2005; 45(4): 758–61

Khan AM, Elahi F, Hashmi SR, Mahida KH, Ingrams DR. Wegener’s granulomatosis: a rare, chronic and multisystem disease. Surgeon 2006; 4(1): 45–52.

Ibrahim S. Focal segmental glomerulosclerosis as the sole renal lesion in Wegener’s granulomatosis. Saudi J Kidney Dis Transpl 2010; 21(6): 1118–21.

Rasmussen N. Management of the ear, nose, and throat manifestations of Wegener granulomatosis: an otorhinolaryngologist’s perspective. Curr Opin Rheumatol. 2011; 13(1): 3-11.

Reinhold-Keller E, Beuge N, Latza U, de Groot K, Rudert H, Nölle B, et al. An interdisciplinary approach to the care of patients with Wegener’s granulomatosis: long-term outcome in 155 patients. Arthritis Rheum. 2000; 43(5): 1021–32.

Vega Braga FL, Machado de Carvalho G, Caixeta Guimarães A, Scaramussa L, Jordão Gusmão R. Otolaryngological Manifestations of Wegener’s Disease. Acta Otorrinolaringol Esp. 2013; 64(1):45-9.

Jennings CR, Jones NS, Dugar J, Powell RJ, Lowe J. Wegener’s granulomatosis - a review of diagnosis and treatment in 53 subjects. Rhinology. 1998; 36(4): 188-91.

Morales-Angulo C, García-Zornoza R, Obeso-Agüera S, Calvo-Alén J, González-Gay MA. Ear, nose and throat manifestations of Wegener’s granulomatosis (granulomatosis with polyangiitis). Acta Otorrinolaringol Esp. 2012; 63(3) 206-11.

Taylor SC, Clayburgh DR, Rosenbaum JT, Schindler JS. Clinical manifestations and treatment of idiopathic and Wegener granulomatosis-associated subglottic stenosis. JAMA Otolaryngol Head Neck Surg. 2013; 139(1):76-81.

Ferri E, Armato E, Capuzzo P, Cavaleri S, Ianniello F. Early diagnosis of Wegener’s granulomatosis presenting with bilateral facial paralysis and bilateral serous otitis media. Auris Nasus Larynx. 2007; 34(3):379-82.

Gómez-Torres A, Tirado I, Abrante A, Esteban F. Wegener’s granulomatosis causing bilateral facial paralysis and deafness. Acta Otorrinolaringol Esp. 2013; 64(2):154-6.

Knight JM, Hayduk MJ, Summerlin DJ, Mirowski GW. “Strawberry” gingival hyperplasia: a pathognomonic mucocutaneous finding in Wegener granulomatosis. Arch Dermatol. 2000; 136(2):171-3.

Ceylan A, Asal K, Çelenk F, Köybaşioğlu A. Parotid gland involvement as a presenting feature of Wegener’s granulomatosis. Singapore Med J. 2013; 54(9): 196-8.

Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum. 1990; 33(8): 1101-7.

Hagen EC, Rasmussen N; Study Group on ANCA Assay Standardization. Use and abuse of ANCA testing. Rheumatology in Europe 1997, 26:126–129.

Thai LH, Charles P, Resche-Rigon M, Desseaux K, Guillevin L. Are anti-proteinase-3 ANCA a useful marker of granulomatosis with polyangiitis (Wegener’s) relapses? Results of a retrospective study on 126 patients. Autoimmun Rev. 2014;13(3) :313-8.

Borner U, Landis BN, Banz Y, Villiger P, Ballinari P, Caversaccio M, et al. Diagnostic value of biopsies in identifying cytoplasmic antineutrophil cytoplasmic antibodynegative localized Wegener’s granulomatosis presenting primarily with sinonasal disease. Am J Rhinol Allergy. 2012; 26(6):475-80.

Vera-Lastra O, Olvera-Acevedo A, McDonal-Vera A, Pacheco- Ruelas M, Gayosso-Rivera JA. [Wegener’s granulomatosis: diagnosis and treatment]. Gac Med Mex. 2009; 145(2):121-9.

Fortin PM, Tejani AM, Bassett K, Musini VM. Intravenous immunoglobulin as adjuvant therapy for Wegener’s granulomatosis. Cochrane Database Syst Rev [Internet]. 2013 Ene 31. Marz [Consultado 2014 Feb 15] 31; 1:CD007057. Disponible en: http://onlinelibrary.wiley.com/

doi/10.1002/14651858.CD007057.pub3/abstract

De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005; 52(8): 2461-9.

Harper L, Morgan MD, Walsh M, Hoglund P, Westman K, Flossmann O, et al; EUVAS investigators. Pulse versus daily oral cyclophosphamide for induction of remission in ANCAassociated vasculitis: long-term follow-up. Ann Rheum Dis. 2012; 71(6): 955-60.

Gaskin G, Pusey CD. Plasmapheresis in antineutrophil cytoplasmic antibody-associated systemic vasculitis. Ther Apher. 2001; 5(3):176-81.

Hellmich B, Lamprecht P, Gross WL. Advances in the therapy of Wegener ́s granulomatosis. Curr Opin Rheumatol 2006; 18(1): 25-32.